Join Growin Stock Community!

Corvus pharmaceuticals, inc.CRVS.US Overview

US StockHealthcare
(No presentation for CRVS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CRVS AI Insights

CRVS Overall Performance

CRVS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CRVS Recent Performance

-4.74%

Corvus pharmaceuticals, inc.

0.05%

Avg of Sector

-0.31%

S&P500

CRVS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CRVS Key Information

CRVS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CRVS Profile

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.

Price of CRVS

CRVS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CRVS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.18
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
21.34
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.18
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
21.34
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is CRVS's latest earnings report released?

    The most recent financial report for Corvus pharmaceuticals, inc. (CRVS) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CRVS's short-term business performance and financial health. For the latest updates on CRVS's earnings releases, visit this page regularly.

  • How much debt does CRVS have?

    As of the end of the reporting period, Corvus pharmaceuticals, inc. (CRVS) had total debt of 1.01M, with a debt ratio of 0.01. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does CRVS have?

    At the end of the period, Corvus pharmaceuticals, inc. (CRVS) held Total Cash and Cash Equivalents of 2.87M, accounting for 0.04 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is CRVS's EPS continuing to grow?

    According to the past four quarterly reports, Corvus pharmaceuticals, inc. (CRVS)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.12. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CRVS?

    Corvus pharmaceuticals, inc. (CRVS)'s Free Cash Flow (FCF) for the period is -9.57M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 51.34% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of CRVS?

    The latest valuation data shows Corvus pharmaceuticals, inc. (CRVS) has a Price-To-Earnings (PE) ratio of -37.85 and a Price/Earnings-To-Growth (PEG) ratio of -0.75. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.